
Positive results in Phase II trial of migaldendranib for DMO and nAMD
Ashvattha Therapeutics has announced positive results in the Phase II trial of migaldendranib (MGB), a targeted nanomedicine for the treatment of diabetic macular oedema (DMO) and neovascular age-related macular degeneration (nAMD). The findings showed the annualised rate of IVT injections in all study eyes decreased from 8.4… Read More



